EMP2 H-scores from 16 tumor samples obtained from patients undergoing initial resection for newly diagnosed glioblastoma were compared to EMP H-scores obtained from 17 patients undergoing subsequent resection after bevacizumab treatment for recurrent glioblastoma (Figure 2A). The gene discussed is EMP2; the disease is glioblastoma.